These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 17075468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The management of ascites and hyponatremia in cirrhosis.
    Ginès P, Cárdenas A.
    Semin Liver Dis; 2008 Feb; 28(1):43-58. PubMed ID: 18293276
    [Abstract] [Full Text] [Related]

  • 3. Hyponatremia in cirrhosis: pathophysiology and management.
    John S, Thuluvath PJ.
    World J Gastroenterol; 2015 Mar 21; 21(11):3197-205. PubMed ID: 25805925
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D, HypoCAT Study Investigators.
    Hepatology; 2008 Jul 21; 48(1):204-13. PubMed ID: 18508290
    [Abstract] [Full Text] [Related]

  • 10. [Hyponatremia in liver cirrhosis: pathogenesis and treatment].
    Guevara M, Ginès P.
    Endocrinol Nutr; 2010 May 21; 57 Suppl 2():15-21. PubMed ID: 21130958
    [Abstract] [Full Text] [Related]

  • 11. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
    Ginès P, Guevara M.
    Hepatology; 2008 Sep 21; 48(3):1002-10. PubMed ID: 18671303
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, Wang X, Wang JF, Lu W, Li CZ, Mao Y, Wang GQ, Gao YQ, Wang B, Zhang Q, Ge Y, Wong VW.
    Ann Hepatol; 2017 Aug 28; 16(1):123-132. PubMed ID: 28051801
    [Abstract] [Full Text] [Related]

  • 15. Hyponatremia in Cirrhosis: An Update.
    Alukal JJ, John S, Thuluvath PJ.
    Am J Gastroenterol; 2020 Nov 28; 115(11):1775-1785. PubMed ID: 33156095
    [Abstract] [Full Text] [Related]

  • 16. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG.
    BMC Gastroenterol; 2018 Sep 04; 18(1):137. PubMed ID: 30180806
    [Abstract] [Full Text] [Related]

  • 17. The association between the serum sodium level and the severity of complications in liver cirrhosis.
    Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, Moon YS.
    Korean J Intern Med; 2009 Jun 04; 24(2):106-12. PubMed ID: 19543488
    [Abstract] [Full Text] [Related]

  • 18. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W, Głuszek J.
    Pol Arch Med Wewn; 2007 Aug 04; 117(8):356-62. PubMed ID: 18018383
    [Abstract] [Full Text] [Related]

  • 19. Hypervolemic Hyponatremia (Liver).
    Solà E, Ginès P.
    Front Horm Res; 2019 Aug 04; 52():104-112. PubMed ID: 32097916
    [Abstract] [Full Text] [Related]

  • 20. Approach and management of dysnatremias in cirrhosis.
    Bernardi M, Zaccherini G.
    Hepatol Int; 2018 Nov 04; 12(6):487-499. PubMed ID: 30203382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.